Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Trial Profile

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sitravatinib (Primary)
  • Indications Carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Sponsors Mirati Therapeutics
  • Most Recent Events

    • 03 Aug 2023 Status changed from Completed to Discontinued.
    • 07 Feb 2023 Status changed from recruiting to Completed.
    • 23 Sep 2020 Protocol amended to add cohort Sitravatinib in combination with Pembrolizumab and Enfortumab vedotin. Planned number of patient and number of arms changed, as reported by ClinicalTrial.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top